'
Epigral hosted a conference call
on Jan 30, 2025. In the conference call the company was represented by Maulik
Patel, Chairman and Managing Director and Rakesh Agarwal.
Key takeaways of the call
In Q3FY26 about 52% of revenue came
from Derivatives and Specialty business
compared to 50% in Q3FY25 and 50% in Q2FY26. Revenue from Chloralkali was 48% in Q3FY26.
Sales volume dropped in 9MFY26
majorly on account of subdued demand because of extended monsoon and lower
volume because of maintenance work at plant.
EBITDA margin stood at 17% in
Q3FY26 down compared to 23% in Q2FY26 on account of drop in realizations and
increase in cost of raw materials. Margins in Q3FY26 reflected temporary
pressures from softer realizations on select products, elevated raw material
costs, and inventory dynamics (higher cost inventory).
Plant utilization in Q3FY26 stood
at 78% similar to previous quarter...
Pleaselogin & subscribe to view the full report.
More Reports
|
|